Quick Answer
Enliven Therapeutics, Inc. reported Research And Development Expense of $85.86 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed an increase of +6.3% in Research And Development Expense from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $3.56 million | Q2 2019: $4.37 million | Q3 2019: $5.14 million | Q1 2020: $5.79 million | Q2 2020: $7.87 million | Q3 2020: $9.53 million | Q1 2021: $7.12 million | Q2 2021: $10.07 million | Q3 2021: $10.40 million | Q1 2022: $7.06 million | Q2 2022: $7.94 million | Q3 2022: $7.83 million | Q1 2023: $11.88 million | Q2 2023: $15.18 million | Q3 2023: $19.61 million | Q1 2024: $19.97 million | Q2 2024: $18.83 million | Q3 2024: $21.26 million | Q1 2025: $24.90 million | Q2 2025: $21.49 million | Q3 2025: $18.23 million.
- Over the full 7 years of available data (2019 to 2025), Enliven Therapeutics, Inc.'s Research And Development Expense has grown by 351.7%.
- Historical annual values: Fiscal year 2025: $85.86 million | Fiscal year 2024: $80.78 million | Fiscal year 2023: $64.57 million | Fiscal year 2022: $31.02 million | Fiscal year 2021: $38.44 million | Fiscal year 2020: $32.15 million | Fiscal year 2019: $19.01 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: